Platinum-based compounds for the treatment of metastatic breast cancer

Chemotherapy

Volumn 57, Issue 6, 2012, Pages 468-487

  Shamseddine, Ali I ^a   Farhat, Fadi S ^b  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b Hammoud Hospital   (Lebanon)

Author keywords

Breast cancer; Carboplatin; Chemotherapy; Cisplatin; Metastasis

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; INIPARIB; IPROPLATIN; MIBOPLATIN; NAVELBINE; NEDAPLATIN; OLAPARIB; OXALIPLATIN; PACLITAXEL; PICOPLATIN; PLATINUM DERIVATIVE; SATRAPLATIN; SEBRIPLATIN; SPIROPLATIN; VINBLASTINE;

ALOPECIA; ANEMIA; ANOREXIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HEARING LOSS; HUMAN; HYPOMAGNESEMIA; KIDNEY FAILURE; LEUKOPENIA; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; STOMATITIS; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; PLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 84855583193     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000334093     Document Type: Review

References (185)

1. Tkaczuk KH: Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin Ther 2009; 31: 2273-2289.
2. Boulikas T, Vougiouka M: Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep 2003; 10: 1663-1682.
3. Galanski M, Jakupec MA, Keppler BK: Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr Med Chem 2005; 12: 2075-2094. (Pubitemid 41093559)
4. Kolaric K, Roth A: Phase II clinical trial of cis-dichlorodiamine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 1983; 11: 108-112. (Pubitemid 13023531)
5. Sledge GW Jr, Loehrer PJ Sr, Roth BJ, Einhorn LH: Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 1988; 6: 1811-1814. (Pubitemid 19089062)
6. Yap HY, Salem P, Hortobagyi GN, Bodey GP Sr, Buzdar AU, Tashima CK, Blumenschein GR: Phase II study of cis-dichlorodi -a mineplatinum(ii) in advanced breast cancer. Cancer Treat Rep 1978; 62: 405-408. (Pubitemid 8335906)
7. Ostrow S, Egorin M, Aisner J, Bachur N, Wiernik PH: High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy. Cancer Clin Trials 1980; 3: 23-27. (Pubitemid 10040553)
8. Forastiere AA, Hakes TB, Wittes JT, Wittes RE: Cisplatin in the treatment of metastatic breast carcinoma: a prospective randomized trial of two dosage schedules. Am J Clin Oncol 1982; 5: 243-247. (Pubitemid 12058960)
9. Martino S, Samal BA, Singhakowinta A, Yoshida S, Mackenzie M, Jain J, Vaitkevicius VK: A phase II study of cis-diamminedichloroplatinum II for advanced breast cancer. Two dose schedules. J Cancer Res Clin Oncol 1984; 108: 354-356. (Pubitemid 15211818)
10. Bajorin D, Bosl GJ, Fein R: Phase I trial of escalating doses of cisplatin in hypertonic saline. J Clin Oncol 1987; 5: 1589-1593. (Pubitemid 18010136)
11. Ramnath N, LoRusso P, Simon M, Martino S: Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer. Am J Clin Oncol 1997; 20: 368-372. (Pubitemid 27329569)
12. Kolaric K, Vukas D: Carboplatin activity in untreated metastatic breast cancer patients -results of a phase II study. Cancer Chemother Pharmacol 1991; 27: 409-412.
13. Martin M, Diaz-Rubio E, Casado A, Santabarbara P, Lopez Vega JM, Adrover E, Lenaz L: Carboplatin: an active drug in metastatic breast cancer. J Clin Oncol 1992; 10: 433-437.
14. O'Brien ME, Talbot DC, Smith IE: Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. J Clin Oncol 1993; 11: 2112-2117. (Pubitemid 23332246)
15. Mathe G, Kidani Y, Triana K, Brienza S, Ribaud P, Goldschmidt E, Ecstein E, Despax R, Musset M, Misset JL: A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP). Biomed Pharmacother 1986; 40: 372-376. (Pubitemid 17052721)
16. Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B, Mathe G: Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990; 82: 1046-1050. (Pubitemid 20204976)
17. Garufi C, Nistico C, Brienza S, Vaccaro A, D'Ottavio A, Zappala AR, Aschelter AM, Terzoli E: Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study. Ann Oncol 2001; 12: 179-182. (Pubitemid 32223864)
18. Casper ES, Smart TC, Hakes TB, Ochoa M Jr, Kaufman RJ: Clinical trial of iproplatin (cisdichloro-trans-dihydroxy-bis-isopropylamine platinum IV, CHIP) in patients with advanced breast cancer. Invest New Drugs 1988; 6: 87-91.
19. Meisner DJ, Ginsberg S, Ditch A, Louie A, Newman N, Comis R, Poiesz B: A phase II trial of iproplatin (CHIP) in previously treated advanced breast cancer. Am J Clin Oncol 1989; 12: 129-131. (Pubitemid 19111591)
20. Vermorken JB, Gundersen S, Clavel M, Smyth JF, Dodion P, Renard J, Kaye SB: Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer. The EORTC Early Clinical Trials Group and the EORTC Data Center. Ann Oncol 1993; 4: 303-306. (Pubitemid 23139370)
21. Kurata T, Tamura T, Sasaki Y, Fujii H, Negoro S, Fukuoka M, Saijo N: Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro- cyclohexylamineplatinum( IV) (JM216) administered once a day for five consecutive days: a phase I study. Jpn J Clin Oncol 2000; 30: 377-384.
22. Smith JW 2nd, McIntyre KJ, Acevedo PV, Encarnacion CA, Tedesco KL, Wang Y, Asmar L, O'Shaughnessy JA: Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer. Breast Cancer Res Treat 2009; 118: 361-367.
23. Koyama H, Ogawa M, Kuraishi Y, Tominaga K, Yoshida M, Taguchi T: A phase II clinical study of cis-diammine glycolato platinum, 254-S, for advanced breast cancer (in Japanese). Gan To Kagaku Ryoho 1992; 19: 1049-1053.
24. Tanis BC, Vermorken JB, ten Bokkel Huinink WW, Klein I, Gall H, van Oosterom AT, Simonetti G, McVie JG, van der Vijgh WJ, Pinedo HM: Phase I study of spiroplatin. Eur J Cancer 1991; 27: 268-273.
25. Tanis BC, Vermorken JB, ten Bokkel Huinink WW, van Oosterom AT, Splinter TA, Vendrik KJ, Sleijfer DT, van der Burg ME, van der Putten E, Pinedo HM: Multicenter phase II study of spiroplatin. Oncology 1992; 49: 99-103.
26. Theriault RL, Cohen IA, Esparza L, Kowal C, Raber MN: Phase I clinical evaluation of [SP-4-3(R)]-[1,1-cyclobutanedicarboxylato(2-)] (2-methyl-1,4-butanediamine-N,N1) platinum in patients with metastatic solid tumors. Cancer Chemother Pharmacol 1993; 31: 333-337. (Pubitemid 23029161)
27. Theriault RL, Walters RS, Holmes FA, Esparza-Guerra L, Kowal C, Hortobagyi GN: A phase II study of CI-973 [SP-4-3(R)]-1,1-cyclobutane- dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N, N') platinum in patients with refractory advanced breast cancer. Cancer Chemother Pharmacol 1996; 38: 289-291.
28. Gelmon KA, Vandenberg TA, Panasci L, Norris B, Crump M, Douglas L, Walsh W, Matthews SJ, Seymour LK: A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group trial, IND 129. Ann Oncol 2003; 14: 543-548. (Pubitemid 41295080)
29. Akamatsu K, Saito H, Tsunenari T, Matsumoto T, Morikawa K, Koizumi M, Mitsui H, Koizumi K: In vitro antitumor activity of a new platinum complex, DWA2114R against human tumor cell lines. Anticancer Res 1993; 13: 2261-2265. (Pubitemid 24036360)
30. Aoyama H, Kubo K, Uchino J, Hayasaka H, Asaishi K, Izuo M, Ogawa M, Majima H, Yasutomi M, Wada T, et al: A phase II study of DWA2114R, a new platinum complex for breast cancer (in Japanese). Gan To Kagaku Ryoho 1992; 19: 1033-1039.
31. Schabel FM Jr, Trader MW, Laster WR Jr, Corbett TH, Griswold DP Jr: Cis-dichlorodiammineplatinum( II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 1979; 63: 1459-1473. (Pubitemid 10167741)
32. Durand RE, Goldie JH: Interaction of etoposide and cisplatin in an in vitro tumor model. Cancer Treat Rep 1987; 71: 673-679.
33. Cocconi G, Bisagni G, Bacchi M, Boni C, Bartolucci R, Ceci G, Colozza MA, De Lisi V, Lottici R, Mosconi AM, et al: Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1991; 9: 664-669.
34. Lluch A, Azagra P, Cervantes A, Munoz M, Alberola V, Santabarbara P, Garcia-Conde J: Phase II trial of cisplatin and etoposide as first-line therapy in metastatic breast carcinoma. Oncology 1994; 51: 352-355. (Pubitemid 24185137)
35. Franciosi V, Cocconi G, Michiara M, Di Costanzo F, Fosser V, Tonato M, Carlini P, Boni C, Di Sarra S: Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999; 85: 1599-1605. (Pubitemid 29152834)
36. Decatris MP, Sundar S, O'Byrne KJ: Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev 2004; 30: 53-81. (Pubitemid 38240088)
37. Cocconi G, Tonato M, Di Costanzo F, Bisagni G, Belsanti V, Buzzi F, Ceci G: Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Eur J Cancer Clin Oncol 1986; 22: 761-764. (Pubitemid 16071295)
38. Athanassiades P, Bacoyiannes H, Kontoyiannes D: Etoposide (VP-16-213) and cis-dichlorodiammineplatinum (DDP) in advanced breast carcinoma resistant to previous chemotherapy. Chemioterapia 1986; 5: 125-127. (Pubitemid 16115198)
39. Giaccone G, Donadio M, Ferrati P, Calciati A: Cisplatin and etoposide in chemotherapyrefractory advanced breast cancer. Tumori 1988; 74: 191-193.
40. Cox EB, Burton GV, Olsen GA, Vugrin D: Cisplatin and etoposide: an effective treatment for refractory breast carcinoma. Am J Clin Oncol 1989; 12: 53-56. (Pubitemid 19037253)
41. Krook JE, Loprinzi CL, Schaid DJ, Kardinal CG, Mailliard JA, Pfeifle DM, Ellison NM, Reuter NF, Nelimark RA: Evaluation of the continuous infusion of etoposide plus cisplatin in metastatic breast cancer. A collaborative North Central Cancer Treatment Group/ Mayo Clinic phase II study. Cancer 1990; 65: 418-421.
42. Icli F, Gunel N, Dincol D, Karaoguz H, Demirkazik A: Cisplatin plus VP-16 combination chemotherapy in advanced refractory breast cancer. J Surg Oncol 1992; 50: 251-253.
43. Ceci G, Bisagni G, Cocconi G, Rodino C, Belsanti V, Bertusi M, Buzzi F, Bacchi M: Cisplatin and VP16 in metastatic breast carcinoma as a third-line chemotherapy: a randomized study comparing low versus high doses of cisplatin. Tumori 1995; 81: 241-244.
44. Remick SC, Chmura M, Bromberg C, Sporn J, Healey B, Hilstro J, DeConti RC, Horton J, Ruckdeschel JC, Harper GR: Concurrent 72-hour continuous infusion of etoposide and cisplatin in metastatic breast cancer. Am J Clin Oncol 1996; 19: 125-131. (Pubitemid 26108213)
45. Fried G, Stein ME, Haim N: Clinical activity of cisplatin and prolonged oral administration of etoposide in previously treated, anthracycline-resistant, metastatic breast cancer patients: a phase II study. Med Pediatr Oncol 2000; 34: 10-13. (Pubitemid 30022702)
46. Braybrooke JP, Levitt NC, Joel S, Davis T, Madhusudan S, Turley H, Wilner S, Harris AL, Talbot DC: Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression. Clin Cancer Res 2003; 9: 4682-4688. (Pubitemid 37323269)
47. Icli F, Akbulut H, Uner A, Yalcin B, Baltali E, Altinbas M, Coskun S, Komurcu S, Erkisi M, Demirkazik A, Senler FC, Sencan O, Buyukcelik A, Boruban C, Onur H, Zengin N, Sak SD: Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. Br J Cancer 2005; 92: 639-644. (Pubitemid 40460597)
48. Deltetto F, Durando A, Camanni M, Pesola D, Sberveglieri M, Arese P, Massobrio M: Carboplatin plus etoposide regimen in advanced breast cancer. A phase II study. Eur J Gynaecol Oncol 1997; 18: 185-187. (Pubitemid 27229442)
49. van der Gaast A, Bontenbal M, Planting AS, Kok TC, Splinter TA: Phase II study of carboplatin and etoposide as a first line regimen in patients with metastatic breast cancer. Ann Oncol 1994; 5: 858-860. (Pubitemid 24341883)
50. Crown J, Hakes T, Reichman B, Lebwohl D, Gilewski T, Surbone A, Currie V, Yao TJ, Hudis C, Seidman A, et al: Phase II trial of carboplatin and etoposide in metastatic breast cancer. Cancer 1993; 71: 1254-1257. (Pubitemid 23054915)
51. Fountzilas G, Skarlos D, Theoharis D, Giannakakis T, Stathopoulos G: Carboplatin and oral etoposide in the treatment of patients with advanced breast cancer refractory to anthracyclines. Tumori 1993; 79: 389-392. (Pubitemid 24124183)
52. Ron IG, Vishne TH, Kraminsky N, Bar-Am A, Inbar MJ: Phase II study of carboplatin and etoposide as salvage treatment for patients with metastatic breast cancer. Am J Clin Oncol 1999; 22: 35-37. (Pubitemid 30261587)
53. Vinolas N, Daniels M, Estape J, Grau JJ, Palombo H, Sola C: Phase II trial of carboplatin and etoposide activity in pretreated breast cancer patients. Am J Clin Oncol 1992; 15: 160-162.
54. Barker LJ, Jones SE, Savin MA, Mennel RG: Phase II evaluation of carboplatin and VP-16 for patients with metastatic breast cancer and only one prior chemotherapy regimen. Cancer 1993; 72: 771-773. (Pubitemid 23215263)
55. Gelmon KA, O'Reilly SE, Tolcher AW, Campbell C, Bryce C, Ragaz J, Coppin C, Plenderleith IH, Ayers D, McDermott B, Nakashima L, Healey D, Onetto N: Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 1996; 14: 1185-1191. (Pubitemid 26105525)
56. Wasserheit C, Frazein A, Oratz R, Sorich J, Downey A, Hochster H, Chachoua A, Wernz J, Zeleniuch-Jacquotte A, Blum R, Speyer J: Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J Clin Oncol 1996; 14: 1993-1999. (Pubitemid 26230099)
57. Ezzat A, Raja MA, Berry J, Bazarbashi S, Zwaan F, Rahal M, el-Warith A: A phase II trial of circadian-timed paclitaxel and cisplatin therapy in metastatic breast cancer. Ann Oncol 1997; 8: 663-667. (Pubitemid 27372164)
58. Sparano JA, Neuberg D, Glick JH, Robert NJ, Goldstein LJ, Sledge GW, Wood W: Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1997; 15: 1880-1884. (Pubitemid 27209517)
59. Frasci G, Comella P, D'Aiuto G, Budillon A, Barbarulo D, Thomas R, Capasso I, Casaretti R, Daponte A, Caponigro F, Gravina A, Maiorino L, Carateni G, Gentile A, Comella G: Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study. Breast Cancer Res Treat 1998; 49: 13-26. (Pubitemid 28279577)
60. Hsu C, Huang CS, Chao TY, Lu YS, Bu CF, Chen MM, Chang KJ, Cheng AL: Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naive patients with locally advanced or metastatic breast carcinoma. Cancer 2002; 95: 2044-2050. (Pubitemid 35253364)
61. Maiche AG, Jekunen AP, Kaleva-Kerola J, Blanco Sequeiros G: High response rate with a lower dose of paclitaxel in combination with cisplatin in heavily pretreated patients with advanced breast carcinoma. Cancer 2000; 88: 1863-1868. (Pubitemid 30212996)
62. Rosati G, Riccardi F, Tucci A, De Rosa P, Pacilio G: A phase II study of paclitaxel/cisplatin combination in patients with metastatic breast cancer refractory to anthracyclinebased chemotherapy. Tumori 2000; 86: 207-210. (Pubitemid 30470739)
63. Vassilomanolakis M, Koumakis G, Barbounis V, Demiri M, Panopoulos C, Chrissohoou M, Apostolikas N, Efremidis AP: Firstline chemotherapy with docetaxel and cisplatin in metastatic breast cancer. Breast 2005; 14: 136-141. (Pubitemid 40353041)
64. Wang YJ, Wu Q, Su FX, Zhou LZ, Ye ZB, Yang JQ, Ren H, Zhang J, Ding G, Fu Q, Wang N: Phase II study of docetaxel plus epirubicin versus docetaxel plus cisplatin as first-line chemotherapy for advanced breast cancer (in Chinese). Zhonghua Zhong Liu Za Zhi 2008; 30: 541-544.
65. Cortes JE, Pazdur R: Docetaxel. J Clin Oncol 1995; 13: 2643-2655.
66. Spielmann M, Llombart A, Zelek L, Sverdlin R, Rixe O, Le Cesne A: Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer. Ann Oncol 1999; 10: 1457-1460. (Pubitemid 30017055)
67. Park SH, Cho EK, Bang SM, Shin DB, Lee JH, Lee YD: Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial. BMC Cancer 2005; 5: 21.
68. Xu BH, Zhao LM, Wang JY, Yuan P: Docetaxel combined with cisplatin in the treatment of anthracycline-resistant advanced breast cancer (in Chinese). Zhonghua Zhong Liu Za Zhi 2006; 28: 471-473.
69. Ahn JH, Kim SB, Sohn HJ, Lee JS, Kang YK, Kun Kim W: Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines. Breast 2005; 14: 304-309.
70. Lin YC, Chang HK, Chen JS, Wang HM, Yang TS, Liaw CC: A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis. Jpn J Clin Oncol 2007; 37: 23-29.
71. Fountzilas G, Dimopoulos AM, Papadimitriou C, Kalogera-Fountzila A, Aravantinos G, Bafaloukos D, Athanassiades A, Nicolaides C, Keramopoulos A, Pavlidis N, Kosmidis P, Skarlos D: First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1998; 9: 1031-1034. (Pubitemid 28496715)
72. Loesch D, Robert N, Asmar L, Gregurich MA, O'Rourke M, Dakhil S, Cox E: Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J Clin Oncol 2002; 20: 3857-3864.
73. Perez EA, Hillman DW, Stella PJ, Krook JE, Hartmann LC, Fitch TR, Hatfield AK, Mailliard JA, Nair S, Kardinal CG, Ingle JN: A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 2000; 88: 124-131. (Pubitemid 30027687)
74. Fountzilas G, Kalofonos HP, Dafni U, Papadimitriou C, Bafaloukos D, Papakostas P, Kalogera-Fountzila A, Gogas H, Aravantinos G, Moulopoulos LA, Economopoulos T, Pectasides D, Maniadakis N, Siafaka V, Briasoulis E, Christodoulou C, Tsavdaridis D, Makrantonakis P, Razis E, Kosmidis P, Skarlos D, Dimopoulos MA: Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2004; 15: 1517-1526. (Pubitemid 39409743)
75. Fountzilas G, Dafni U, Dimopoulos MA, Koutras A, Skarlos D, Papakostas P, Gogas H, Bafaloukos D, Kalogera-Fountzila A, Samantas E, Briasoulis E, Pectasides D, Maniadakis N, Matsiakou F, Aravantinos G, Papadimitriou C, Karina M, Christodoulou C, Kosmidis P, Kalofonos HP: A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 2009; 115: 87-99.
76. Perez EA, Suman VJ, Fitch TR, Mailliard JA, Ingle JN, Cole JT, Veeder MH, Flynn PJ, Walsh DJ, Addo FK: A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932. Oncology 2005; 69: 117-121. (Pubitemid 41376909)
77. Mavroudis D, Alexopoulos A, Malamos N, Ardavanis A, Kandylis C, Stavrinidis E, Kouroussis C, Agelaki S, Androulakis N, Bozionelou V, Georgoulias V: Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial. Oncology 2003; 64: 207-212. (Pubitemid 36438804)
78. Kouroussis C, Agelaki S, Mavroudis D, Kakolyris S, Androulakis N, Kalbakis K, Souglakos J, Mallas K, Bozionelou V, Pallis A, Adamtziki H, Georgoulias V: A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer. Anticancer Res 2003; 23: 785-791. (Pubitemid 36358489)
79. Qu G, Perez EA: Gemcitabine and targeted therapy in metastatic breast cancer. Semin Oncol 2002; 29: 44-52. (Pubitemid 34816065)
80. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995; 22: 72-79.
81. Mohran TZ: Gemcitabine and cisplatin combination chemotherapy as a first-line treatment in patients with metastatic breast cancer. J Egypt Natl Canc Inst 2004; 16: 8-14.
82. Fuentes H, Calderillo G, Alexander F, Ramirez M, Avila E, Perez L, Aguirre G, Onate-Ocana LF, Gallardo D, Otero J: Phase II study of gemcitabine plus cisplatin in metastatic breast cancer. Anticancer Drugs 2006; 17: 565-570. (Pubitemid 44309973)
83. Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS: Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 2000; 18: 2245-2249. (Pubitemid 30350216)
84. Burch PA, Mailliard JA, Hillman DW, Perez EA, Krook JE, Rowland KM, Veeder MH, Cannon MW, Ingle JN: Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial. Am J Clin Oncol 2005; 28: 195-200.
85. Semiglazova T, Filatova LV, Gershanovich ML: Gemcitabine plus cisplatin therapy in breast cancer refractory to anthracyclines, docetaxel and capecitabine (in Russian). Vopr Onkol 2005; 51: 66-70. (Pubitemid 40445297)
86. Heinemann V, Stemmler HJ, Wohlrab A, Bosse D, Losem C, Kahlert S, Rauthe G: High efficacy of gemcitabine and cisplatin in patients with predominantly anthracyclineand taxane-pretreated metastatic breast cancer. Cancer Chemother Pharmacol 2006; 57: 640-646. (Pubitemid 43237849)
87. Seo JH, Oh SC, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS, Kim AR, Lee JB, Koo BH: Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer. Cancer Chemother Pharmacol 2007; 59: 269-274. (Pubitemid 44885156)
88. Sanchez-Escribano Morcuende R, Ales-Martinez JE, Aramburo Gonzalez PM: Low dose gemcitabine plus cisplatin in a weeklybased regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens. Clin Transl Oncol 2007; 9: 459-464.
89. Kim JH, Oh SY, Kwon HC, Lee S, Kim SH, Kim DC, Lee JH, Lee HS, Cho SH, Kim HJ: Phase II study of gemcitabine plus cisplatin in patients with anthracycline-and taxanepretreated metastatic breast cancer. Cancer Res Treat 2008; 40: 101-105.
90. Tas F, Guney N, Derin D, Camlica H, Aydiner A, Topuz E: Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer. Invest New Drugs 2008; 26: 363-368.
91. Somali I, Alacacioglu A, Tarhan MO, Meydan N, Erten C, Usalp S, Yilmaz U: Cisplatin plus gemcitabine chemotherapy in taxane/ anthracycline-resistant metastatic breast cancer. Chemotherapy 2009; 55: 155-160.
92. Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz HJ, Gordon M, Zhang W, Yang D, Russell C, Spicer D, Synold T, Bayer R, Hantel A, Stiff PJ, Tetef ML, Gandara DR, Albain KS: Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol 2009; 27: 2163-2169.
93. Nasr FL, Chahine GY, Kattan JG, Farhat FS, Mokaddem WT, Tueni EA, Dagher JE, Ghosn MG: Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer. Clin Breast Cancer 2004; 5: 117-122, discussion 123-124. (Pubitemid 39029202)
94. Laessig D, Stemmler HJ, Vehling-Kaiser U, Fasching PA, Melchert F, Kolbl H, Stauch M, Maubach P, Scharl A, Morack G, Meerpohl H, Weber B, Kalischefski B, Heinemann V: Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer. Oncology 2007; 73: 407-414. (Pubitemid 351862038)
95. Nagourney RA, Flam M, Link J, Hager S, Blitzer J, Lyons W, Sommers BL, Evans S: Carboplatin plus gemcitabine repeating doublet therapy in recurrent breast cancer. Clin Breast Cancer 2008; 8: 432-435.
96. Chan D, Yeo WL, Tiemsim Cordero M, Wong CI, Chuah B, Soo R, Tan SH, Lim SE, Goh BC, Lee SC: Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes. Invest New Drugs 2010; 28: 859-865.
97. Bozionelou V, Kalbakis K, Vamvakas L, Agelaki S, Androulakis N, Kalykaki A, Georgoulias V, Mavroudis D: A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer. Cancer Chemother Pharmacol 2009; 64: 785-791.
98. Koshy N, Quispe D, Shi R, Mansour R, Burton GV: Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 2010; 19: 246-248.
99. Staudacher L, Cottu PH, Dieras V, Vincent-Salomon A, Guilhaume MN, Escalup L, Dorval T, Beuzeboc P, Mignot L, Pierga JY: Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol 2011; 22: 848-856.
100. Krockenberger M, Engel JB, Hausler S, Dietl J, Honig A: Prolonged clinical benefit from platinum-based chemotherapy in a patient with metastatic triple negative breast cancer. Eur J Gynaecol Oncol 2009; 30: 449-451.
101. Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, Johnston S, Smith IE: Platinum-based chemotherapy in triplenegative breast cancer. Ann Oncol 2008; 19: 1847-1852.
102. Maisano R, Zavettieri M, Azzarello D, Raffaele M, Maisano M, Bottari M, Nardi M: Carboplatin and gemcitabine combination in metastatic triple-negative anthracyclineand taxane-pretreated breast cancer patients: a phase II study. J Chemother 2011; 23: 40-43.
103. Fernandez Hidalgo O, Gonzalez F, Gil A, Campbell W, Barrajon E, Lacave AJ: 120 hours simultaneous infusion of cisplatin and fluorouracil in metastatic breast cancer. Am J Clin Oncol 1989; 12: 397-401. (Pubitemid 19251386)
104. Jones AL, Smith IE, O'Brien ME, Talbot D, Walsh G, Ramage F, Robertshaw H, Ashley S: Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. J Clin Oncol 1994; 12: 1259-1265. (Pubitemid 24173942)
105. Klaassen U, Wilke H, Weyhofen R, Harstrick A, Eberhardt W, Muller C, Korn M, Hanske M, Diergarten K, Seeber S: Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for firstline treatment of metastatic breast cancer. Anticancer Drugs 1998; 9: 203-207. (Pubitemid 28186517)
106. Nole F, Munzone E, Mandala M, Catania C, Orlando L, Zampino MG, Minchella I, Colleoni M, Peruzzotti G, Marrocco E, Goldhirsch A: Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: a phase II study. Ann Oncol 2001; 12: 95-100. (Pubitemid 32162453)
107. Amoroso D, Pronzato P, Bertelli G, Gallotti P, Pastorino G, Cusimano MP, Merlano M, Conte PF, Rosso R: Cisplatin and 5-fluorouracil in refractory breast cancer patients: a phase II study. Breast Cancer Res Treat 1988; 11: 269-271.
108. Fumoleau P, Bastit P, Horner D, Chauvergne J, Metz R, Bugat R, Cappelaere P: Phase II trial as 2nd line chemotherapy with 5 fluorouracil and cisplatin (5FU-CDDP) for advanced breast cancer (in French). Bull Cancer 1990; 77: 805-810. (Pubitemid 20257765)
109. Bitran JD, Kozloff MF, Desser RK: Platinol (CDDP) and continuous intravenous infusion 5-fluorouracil in refractory stage IV breast cancer: a phase II study. Cancer Invest 1990; 8: 335-338. (Pubitemid 20352765)
110. Palacio I, Buesa JM, Baron FJ, Lopez R, Cueva JF, Esteban E, Estrada E, Gracia JM, Lacave AJ: Inefficiency of cisplatin plus 5-FU as second-or third line treatment in advanced breast cancer. Ann Oncol 1991; 2: 521.
111. Spaeth D, Conroy T, Krakowski I, Geoffrois L, Luporsi E, Rios M, Weber B: Long term continuous combination of cisplatin and 5 fluorouracil in advanced breast neoplasms. A retrospective study of 77 patients (in French). Bull Cancer 1993; 80: 351-356. (Pubitemid 23138505)
112. Kucuk O, Pandya KJ, Skeel RT, Hochster H, Abeloff MD: Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185). Breast Cancer Res Treat 1999; 57: 201-206. (Pubitemid 29531465)
113. Booser DJ, Walters RS, Holmes FA, Hortobagyi GN: Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatin for relapsed metastatic breast cancer: a phase II study. Am J Clin Oncol 2000; 23: 40-41. (Pubitemid 30407356)
114. Coskun U, Gunel N, Yamac D, Altinova AE: Effect of cisplatin on skin metastasis in breast cancer patients. Onkologie 2001; 24: 576-579. (Pubitemid 34088235)
115. Eisen T, Smith IE, Johnston S, Ellis PA, Prendiville J, Seymour MT, Walsh G, Ashley S: Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. J Clin Oncol 1998; 16: 1350-1357. (Pubitemid 28175750)
116. Bonnefoi H, Smith IE, O'Brien ME, Seymour MT, Powles TJ, Allum WH, Ebbs S, Baum M: Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen. Br J Cancer 1996; 73: 391-396.
117. Zelek L, Cottu P, Tubiana-Hulin M, Vannetzel JM, Chollet P, Misset JL, Chouaki N, Marty M, Gamelin E, Culine S, Dieras V, Mackenzie S, Spielmann M: Phase II study of oxaliplatin and fluorouracil in taxaneand anthracycline- pretreated breast cancer patients. J Clin Oncol 2002; 20: 2551-2558. (Pubitemid 34525743)
118. Thuss-Patience PC, von Minckwitz G, Kretzschmar A, Loibl S, Schaller G, Dorken B, Reichardt P: Oxaliplatin and 5-fluorouracil for heavily pretreated metastatic breast cancer: a preliminary phase II study. Anticancer Drugs 2003; 14: 549-553. (Pubitemid 37083160)
119. Delozier T, Guastalla JP, Yovine A, Levy C, Chollet P, Mousseau M, Delva R, Coeffic D, Vannetzel JM, Zazzi ES, Brienza S, Cvitkovic E: A phase II study of an oxaliplatin/ vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer. Anticancer Drugs 2006; 17: 1067-1073. (Pubitemid 44454784)
120. Gourley C, Cassidy J, Edwards C, Samuel L, Bisset D, Camboni G, Young A, Boyle D, Jodrell D: A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer. Cancer Chemother Pharmacol 2004; 53: 95-101. (Pubitemid 38186986)
121. Oster MW, Schilsky RL, Faraggi D, Korzun AH, Perry M, Moore A, Kalra J, Wood WC, Henderson IC: Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the Cancer and Leukemia Group B. Cancer 1991; 68: 1696-1698.
122. Mao W, Guan X, Tucker S, Li F, He Z, Wang J, Guo J, Wu S: Second-line combination chemotherapy with vinorelbine and capecitabine in patients with advanced breast cancer previously treated with anthracyclines and/or taxanes. Chemotherapy 2011; 57: 71-76.
123. Taguchi T, Nakayama T, Masuda N, Yoshidome K, Akagi K, Nishida Y, Yoshikawa Y, Ogino N, Abe C, Sakamoto J, Noguchi S: Study of low-dose capecitabine monotherapy for metastatic breast cancer. Chemotherapy 2010; 56: 166-170.
124. Fan Y, Xu B, Yuan P, Wang J, Ma F, Li Q, Zhang P, Cai R: Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Chemotherapy 2010; 56: 340-347.
125. Oksuzoglu B, Abali H, Hayran M, Yildirim N, Budakoglu B, Zengin N: Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes. Chemotherapy 2008; 54: 352-356.
126. Donadio M, Ardine M, Berruti A, Beano A, Bottini A, Mistrangelo M, Bonardi S, Castiglione F, Generali D, Polimeni MA, Bretti S, Alabiso O, Bertetto O: Weekly cisplatin plus capecitabine in metastatic breast cancer patients heavily pretreated with both anthracycline and taxanes. Oncology 2005; 69: 408-413. (Pubitemid 41797917)
127. Polyzos A, Gogas H, Markopoulos C, Tsavaris N, Papadopoulos O, Polyzos K, Giannopoulos A: Salvage chemotherapy with oxaliplatin and capecitabine for breast cancer patients pretreated with anthracyclines and taxanes. Anticancer Res 2009; 29: 2851-2856.
128. Mustacchi G, Muggia M, Milani S, Ceccherini R, Leita ML, Dellach C: A phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer. Ann Oncol 2002; 13: 1730-1736. (Pubitemid 35439452)
129. Sharma RA, Decatris MP, Santhanam S, Roy R, Osman AE, Clarke CB, Khanna S, O'Byrne KJ: Reversibility of liver failure secondary to metastatic breast cancer by vinorelbine and cisplatin chemotherapy. Cancer Chemother Pharmacol 2003; 52: 367-370. (Pubitemid 37363608)
130. Zheng H, Luo RC, You CX: Clinical observation of the efficacy of navelbine combined with ifosfamide and cisplatin in the treatment of advanced breast cancer (in Chinese). Di Yi Jun Yi Da Xue Xue Bao 2003; 23: 1088-1089, 1092.
131. Shamseddine A, Khalifeh M, Chehal A, Saliba T, Mourad YA, Taher A, Jalloul R, Bitar N, Dandashi A, Abbas J, Geara FB: A clinical phase II study of cisplatinum and vinorelbine (PVn) in advanced breast carcinoma (ABC). Am J Clin Oncol 2005; 28: 393-398. (Pubitemid 41099545)
132. Shamseddine AI, Otrock ZK, Khalifeh MJ, Yassine HR, Charafeddine M, Abdel-Khalek Z, Chehal A, Bitar N, Jalloul R, Dheiny M, Dandashi A, Wehbeh M, El-Saghir NS: A clinical phase II study of a nonanthracycline sequential combination of cisplatin-vinorelbine followed by docetaxel as first-line treatment in metastatic breast cancer. Oncology 2006; 70: 330-338. (Pubitemid 46074942)
133. Ray-Coquard I, Biron P, Bachelot T, Guastalla JP, Catimel G, Merrouche Y, Droz JP, Chauvin F, Blay JY: Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline-and/or paclitaxel-containing regimens. Cancer 1998; 82: 134-140. (Pubitemid 28070489)
134. Shamseddine AI, Taher A, Dabaja B, Dandashi A, Salem Z, El Saghir NS: Combination cisplatin-vinorelbine for relapsed and chemotherapy-pretreated metastatic breast cancer. Am J Clin Oncol 1999; 22: 298-302. (Pubitemid 30263327)
135. Gunel N, Akcali Z, Yamac D, Onuk E, Yilmaz E, Bayram O, Tekin E, Coskun U: Cisplatin plus vinorelbine as a salvage regimen in refractory breast cancer. Tumori 2000; 86: 283-285. (Pubitemid 30644901)
136. Vassilomanolakis M, Koumakis G, Barbounis V, Demiri M, Pateras H, Efremidis AP: Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines. Ann Oncol 2000; 11: 1155-1160.
137. Szatkowska L, Mazurkiewicz M, Brzozowska A: Cisplatin and vinorelbine therapy of previously treated advanced breast cancer (preliminary studies) (in Polish). Pol Merkur Lekarski 2001; 10: 148-149.
138. Vassilomanolakis M, Koumakis G, Demiri M, Missitzis J, Barbounis V, Efremidis AP: Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment. Cancer Invest 2003; 21: 497-504. (Pubitemid 37169552)
139. Kosmas C, Agelaki S, Giannakakis T, Mavroudis D, Kouroussis C, Kalbakis K, Papadouris S, Souglakos J, Malamos N, Georgoulias V: Phase I study of vinorelbine and carboplatin combination in patients with taxane and anthracycline pretreated advanced breast cancer. Oncology 2002; 62: 103-109. (Pubitemid 34253078)
140. Iaffaioli RV, Tortoriello A, Facchini G, Santangelo M, De Sena G, Gesue G, Bucci L, Scaramellino G, Anastasio E, Finizio A, et al: A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer. Br J Cancer 1995; 72: 1256-1258.
141. Kakolyris S, Kouroussis C, Koukourakis M, Mavroudis D, Malas K, Vardakis N, Bozionelou V, Kalbakis K, Georgoulias V: A doseescalation study of oxaliplatin and vinorelbine in patients with advanced solid tumors. Oncology 2002; 63: 213-218. (Pubitemid 36151314)
142. Petit T, Benider A, Yovine A, Bougnoux P, Spaeth D, Maindrault-Goebel F, Serin D, Tigaud JD, Eymard JC, Simon H, Bertaux B, Brienza S, Cvitkovic E: Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline-and taxane-pretreated metastatic breast cancer. Anticancer Drugs 2006; 17: 337-343.
143. Farhat F, Kattan J, Ibrahim K, Bitar N, Haddad N, Tamraz S, Hatoum H, Shamseddine A: Preliminary results of a phase II study of lipoplatin (liposomal cisplatin)-vinorelbine combination as first line treatment in HER2/neu negative metastatic breast cancer (MBC) (abstract). Eur J Cancer Suppl 2010; 8: 192.
144. Hsu C, Yeh KH, Hong RL, Yang CH, Lin MT, Chen YC, Cheng AL: MVP (mitomycin-C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancer. J Formos Med Assoc 1997; 96: 185-188. (Pubitemid 27167912)
145. Urruticoechea A, Archer CD, Assersohn LA, Gregory RK, Verrill M, Mendes R, Walsh G, Smith IE, Johnston SR: Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer. Br J Cancer 2005; 92: 475-479. (Pubitemid 40395527)
146. Decatris MP, Sundar S, O'Byrne KJ: Platinum-based chemotherapy in metastatic breast cancer: The Leicester (U.K.) experience. Clin Oncol (R Coll Radiol) 2005; 17: 249-257. (Pubitemid 40716449)
147. Mechl Z, Sopkova B: CAP (cyclophosphamide, adriamycin, cisplatinum) in the treatment of advanced breast cancer. Neoplasma 1984; 31: 431-435. (Pubitemid 14046553)
148. Verusio C, Bajetta E, Ferrari L, Bartoli C, Valagussa P, Bonadonna G: Cyclophosphamide, adriamycin, and cis-platinum (CAP) in metastatic and locally advanced breast cancer. Am J Clin Oncol 1988; 11: 435-439.
149. Colozza M, Gori S, Mosconi AM, Belsanti V, Basurto C, Rossetti R, Di Costanzo F, Buzzi F, Bacchi M, Davis S, et al: Chemotherapy with cis-platin, doxorubicin, and cyclophosphamide (CAP) in patients with metastatic breast cancer. Am J Clin Oncol 1989; 12: 137-141. (Pubitemid 19111593)
150. Kochupillai V, Gupta P, Misra A: A phase II trial of cyclophosphamide, doxorubicin, and cisplatin in advanced breast cancer. Am J Clin Oncol 1992; 15: 388-391.
151. Cartei G, Marsilio P, Morandini G, Rosa Bian A, Clocchiati L, Galletti D, Sibau A, Cendron R, Cacciavillani C, Cantone A, et al: Cyclophosphamide, adriamycin and platinum (CAP) in the preoperative neoadjuvant phase and the therapy phase (in Italian). Chir Ital 1986; 38: 534-542. (Pubitemid 17230631)
152. Fornasiero A, Daniele O, Aversa SM, Ghiotto C, Morandi P, Fiorentino MV: A 5-day regimen of cyclophosphamide, adriamycin, platinum (CAP) in refractory breast cancer. Chemioterapia 1987; 6: 310-312. (Pubitemid 17137000)
153. Tzekova V, Velikova M, Koynov K, Micheva D, Donchev T: Antitumor effect of combination of cyclophosphamide, adriamycin and platinum (CAP) versus cyclophosphamide, adriamycin and 5-fluorouracil (CAF) in metastatic breast cancer. Neoplasma 1991; 38: 603-607.
154. Zaniboni A, Marpicati P, Simoncini E, Gorni F, Ferrari V, Raffaglio E, Garattini MP, Marini G: Cyclophosphamide, epirubicin and cisplatin (CEP) in advanced breast cancer: preliminary results. Anticancer Res 1987; 7: 813-815.
155. Gebbia V, Borsellino N, Testa A, Latteri MA, Milia V, Valdesi M, Giotta F, Gebbia N, Colucci G: Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM). Anticancer Drugs 1997; 8: 943-948. (Pubitemid 28027092)
156. Dogliotti L, Danese S, Berruti A, Zola P, Buniva T, Bottini A, Richiardi G, Moro G, Farris A, Bau MG, Porcile G: Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study. Cancer Chemother Pharmacol 1998; 41: 333-338. (Pubitemid 28059921)
157. Nielsen D, Dombernowsky P, Larsen SK, Hansen OP, Skovsgaard T: Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study. Cancer Chemother Pharmacol 2000; 46: 459-466.
158. Garrone O, Principe E, Occelli M, Mercuri M, Numico G, Granetto C, Di Costanzo G, Rattazzi PD, Merlano M: A phase II study of epirubicin, vinorelbine and cisplatin in advanced breast cancer. Anticancer Drugs 2004; 15: 23-27. (Pubitemid 39140168)
159. Thurlimann B, Senn HJ, Jungi WF: Anthracycline-carboplatin combination in metastatic breast cancer. J Cancer Res Clin Oncol 1990; 116: 13-14. (Pubitemid 20132847)
160. Casper ES, Curley T, Hakes TB: Phase I clinical trial of doxorubicin and iproplatin combination chemotherapy in patients with breast cancer. Invest New Drugs 1989; 7: 189-193. (Pubitemid 19202358)
161. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994; 9: 1829-1838. (Pubitemid 24194147)
162. Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, Stewart SJ: p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: Association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 1994; 54: 3758-3765.
163. Wang Y, Dong L, Bi Q, Ge X, Zhang X, Wu D, Fu J, Zhang C, Wang C, Li S: Beyond antiangiogenesis: intratumorally injected bevacizumab plays a cisplatin-sensitizing role in squamous cell carcinomas in mice. Chemotherapy 2011; 57: 244-252.
164. Pegram MD, Slamon DJ: Combination therapy with trastuzumab (herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol 1999; 26: 89-95. (Pubitemid 29411438)
165. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/ neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16: 2659-2671. (Pubitemid 28363029)
166. Nabholtz JM, Slamon D: New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (herceptin). Semin Oncol 2001; 28: 1-12.
167. Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M, Riva A, Blitz S, Press MF, Reese D, Lindsay MA, Slamon DJ: Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004; 96: 759-769. (Pubitemid 38771821)
168. Burris H 3rd, Yardley D, Jones S, Houston G, Broome C, Thompson D, Greco FA, White M, Hainsworth J: Phase II trial of trastuzumab followed by weekly paclitaxel/ carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 2004; 22: 1621-1629. (Pubitemid 41079800)
169. Perez EA, Suman VJ, Rowland KM, Ingle JN, Salim M, Loprinzi CL, Flynn PJ, Mailliard JA, Kardinal CG, Krook JE, Thrower AR, Visscher DW, Jenkins RB: Two concurrent phase II trials of paclitaxel/carboplatin/ trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 2005; 6: 425-432. (Pubitemid 43078898)
170. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, Mc-Cullough C, Fuchs L, Slamon D: Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 24: 2786-2792. (Pubitemid 46630577)
171. Ruiz M, Salvador J, Bayo J, Lomas M, Moreno A, Valero M, Bernabe R, Vicente D, Jimenez J, Lopez-Ladron A: Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 2008; 62: 1085-1090.
172. Stemmler HJ, Kahlert S, Brudler O, Beha M, Muller S, Stauch B, Heinemann V: High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study. Clin Oncol (R Coll Radiol) 2005; 17: 630-635. (Pubitemid 41700328)
173. Yardley DA, Burris HA 3rd, Simons L, Spigel DR, Greco FA, Barton JH, Shipley D, Drosick D, Hainsworth JD: A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer. Clin Breast Cancer 2008; 8: 425-431.
174. Loesch D, Asmar L, McIntyre K, Doane L, Monticelli M, Paul D, Vukelja S, Orlando M, Vaughn LG, Zhan F, Boehm KA, O'Shaughnessy JA: Phase II trial of gemcitabine/ carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. Clin Breast Cancer 2008; 8: 178-186. (Pubitemid 351655933)
175. Moulder S, Li H, Wang M, Gradishar WJ, Perez EA, Sparano JA, Pins M, Yang X, Sledge GW: A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group trial. Breast Cancer Res Treat 2010; 119: 663-671.
176. Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D: Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat 2010; 122: 1-7.
177. Hoadley KA, Weigman VJ, Fan C, Sawyer LR, He X, Troester MA, Sartor CI, Rieger-House T, Bernard PS, Carey LA, Perou CM: EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 2007; 8: 258.
178. Oliveras-Ferraros C, Vazquez-Martin A, Lopez-Bonet E, Martin-Castillo B, Del Barco S, Brunet J, Menendez JA: Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA crosslinking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer. Int J Oncol 2008; 33: 1165-1176.
179. Carey LA, Rugo HS, Marcom PK, Irvin W, Ferraro M, Burrows E, He X, Perou CM, Winer EP: TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer (abstract). J Clin Oncol 2008; 26: 1009.
180. Baselga J, Gomez P, Awada A, Greil R, Braga S, Climent M, Wardley A, Zubel A, Groos J, Kaufman B: The addition of cetuximab to cisplatin increases overall response rate and progression-free survival in metastatic triple-negative breast cancer: results of a randomized phase II study (abstract). 35th European Society for Medical Oncology Congress, Milan, 2010, abstract 2740.
181. O'Shaughnessy J, Weckstein DJ, Vukelja SJ, McIntyre K, Krekow L, Holmes F, Asmar L, Blum J: Preliminary results of a randomized phase II study of weekly irinotecan/ carboplatin with or without cetuximab in patients with metastatic breast cancer (abstract). Breast Cancer Res Treat 2007; 106: 308.
182. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C: Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364: 205-214.
183. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-244.
184. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J: High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008; 105: 17079-17084.
185. Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, Holstege H, Liu X, van Drunen E, Beverloo HB, Smith GC, Martin NM, Lau A, O'Connor MJ, Jonkers J: Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008; 14: 3916-3925.